Metformin Recall 2021: More Diabetes Medication Recalled Over Continuing Cancer Risks

After expanding an initial recall in November, Nostrum Laboratories has recalled one additional lot of its 750 mg Metformin HCl Extended Release tablets because they may contain a cancer-causing ingredient – nitrosamine (NMDA) – above the daily limits acceptable by the Food and Drug Administration.

Nostrum initially issued a recall for two lots of 500 mg Metformin HCl Extended Release tablets on Nov. 2, 2020. The recall expanded to include an additional lot of 750 mg Metformin HCl Extended Release tablets on Jan. 4, 2021.

In both instances, the medication, which is used to control blood glucose in adults with Type 2 diabetes, was recalled because of higher than acceptable levels of NDMA, which has been classified as a probable human carcinogen that could cause cancer.

In this recall, the affected medication was packaged in 100-count bottles with an NDC number of 29033-056-01. It has a lot number of MET200601 and an expiration date of July 2022. The drug can be identified as a off-white oblong tablet that is debossed with “NM7” on one side.

The recalled metformin was distributed nationwide to the pharmacy and consumer level by wholesalers from Nostrum.

Consumers that have the affected medication in their possession should contact their healthcare provider for an alternative treatment plan. However, the metformin medication should not be stopped without talking to a healthcare professional first, as the risk be greater than continuing to take the drug.

Those individuals that experience issues related to the recalled diabetes medication should contact their healthcare provider.

Questions about the recall can be directed to Nostrum Laboratories Medical Affairs at 816-308-4941, Monday through Friday, 8 a.m. to 5 p.m. CST, or by email at quality@nostrumpharma.com.

Nostrum said it has not received any reports of adverse reactions related to the drug recall.